The European Medicines Agency (EMA) has listed the neurological disorder Guillain-Barre syndrome, which can cause temporary paralysis, as a "very rare" side effect of the AstraZeneca Covid-19 vaccine.
A causal relationship was "considered at least a reasonable possibility", the EMA said in an update. It comes after a total of 833 cases of the syndrome had been reported worldwide by 31 July, from about 592 million doses of the AstraZeneca "Vaxzevria" shot administered. "GBS should therefore be added to the product information as a side effect of Vaxzevria," the agency said.
Guillain-Barre Syndrome was a "very rare" side effect, occurring in under one in 10,000 people, it added. The disorder is a nerve inflammation that may cause temporary